The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.
Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.
The IPF drug shows surprising promise in heart failure with preserved ejection fraction.
But does it hit hard enough?
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.